It is great to see VitaDOA finally covering rapamycin in greater depth. VitaDAO is a community-owned collective funding early stage longevity research. They fund and help commercialize longevity therapeutics.
It was in 1975 when scientists from Ayerst (now Pfizer) discovered a novel compound called rapamycin (also known as Sirolimus) in bacteria on Rapa Nui (Easter Island) in Chile. In 1999 rapamycin obtained FDA approval for the prevention of acute rejection of renal transplant. Unknown at the time, rapamycin would become the most potent anti-aging drug that humans currently hold.
This is the first article of a two-part series on rapamycin.
Read the Full Article at This Link Below:
VitaDOA: Rapamycin is the most promising aging intervention we currently have